Bruise

Cheung Aesthetics & Wellness Introduces Cutting-Edge Technology to Reverse Aging Without Pain or Downtime

Retrieved on: 
torsdag, maj 2, 2024
Collagen, Hyaluronic acid, FAAD, Skin, Wellness, Lifting, Needle, Patient, Electrotherapy, Ageing, Bruise, Medical imaging

Data shows that for most effective results in reducing wrinkles, lifting muscles, and improving facial contour, patients need four treatments of EMface -- one per week. Optimal results are noticeable 6 to 12 weeks after the last treatment.

Key Points: 
  • WILLOWBROOK, Ill., May 2, 2024 /PRNewswire/ -- Cheung Aesthetics & Wellness , a leading Chicago dermatology practice, is among the first to offer groundbreaking technology that reverses facial aging and reduces wrinkles without discomfort, needles, or downtime.
  • The clinic is hosting "Spring Showcase," a complimentary beauty/makeover event on May 16 for those who want to try the latest technology.
  • "EMface is the wave of the future for those wanting to reverse aging using a non-invasive, painless procedure with no bruising or downtime.
  • The EXION platform also features a painless, radiofrequency micro-needling technology that targets hard to treat areas without discomfort or bruising.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Retrieved on: 
onsdag, april 24, 2024
Urine, Kidney, FDA, Shanda, Embolism, Huber loss, Hepatic encephalopathy, Uric acid, Oliguria, Congestion, Blood volume, Furosemide, Organic acid, Deafness, Erythema, Cerebral edema, Ascites, Tinnitus, History, Thrombosis, Creatinine, NYHA, Dehydration, BUN, Patient, Hypersensitivity, Ototoxicity, Anuria, Glucose, Azotemia, Hypoproteinemia, CO2, Diuresis, Cirrhosis, Chronic kidney disease, Edema, Urinary retention, Bruise, Growth, Benign prostatic hyperplasia, Coma, Heart failure, Pharmaceutical industry

BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

Key Points: 
  • The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility.
  • If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

FSIS ISSUES PUBLIC HEALTH ALERT FOR GROUND BEEF PRODUCTS DUE TO POSSIBLE E. COLI O157:H7 CONTAMINATION

Retrieved on: 
lördag, april 20, 2024
Food safety, Syndrome, Person, Poultry, Dysentery, Independence Avenue, Commerce, Kidney failure, USDA, Human, H7, Dehydration, HUS, TDD, Pallor, Meat, Temperature, Chronic pain, FSIS, Bruise, Office for Civil Rights, Civil and political rights, Poultry farming

WASHINGTON, April 20, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for ground beef products that may be contaminated with E. coli O157:H7.

Key Points: 
  • WASHINGTON, April 20, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for ground beef products that may be contaminated with E. coli O157:H7.
  • FSIS is issuing this public health alert to ensure that consumers are aware that these products should not be consumed.
  • The products have a “Use/Freeze by” date of April 22, 2024, and packaging date of “032824.” The list of products that are subject to the public health alert can be found here .
  • The company notified FSIS that they inadvertently used a portion of the contaminated beef to produce ground beef products that they subsequently shipped into commerce.

Global Dermal Fillers Industry Research 2023-2035: Market Set to Expand; Hyaluronic Acid Dominates with Innovation in Minimally Invasive Aesthetics - ResearchAndMarkets.com

Retrieved on: 
fredag, april 12, 2024
Cosmetics, Retail, Pharmaceutical, Health, Market, Aesthetic Plastic Surgery, Lactic acid, International Society, Hyaluronic acid, Social media, Skin, Injectable filler, Filler (linguistics), Medical tourism, Anesthesia, Patient, Gender, Face, Ageing, Lip, Bruise, Growth

Dermal fillers are a type of injectable treatment which consists of hyaluronic acid in the form of a gel-like substance, also known as facial fillers.

Key Points: 
  • Dermal fillers are a type of injectable treatment which consists of hyaluronic acid in the form of a gel-like substance, also known as facial fillers.
  • Dermal fillers often comprise hyaluronic acid, lactic acid, calcium hydroxyapatite, polymethyl methacrylates and polyacrylamide gels.
  • Of these, 86% of the procedures were done using hyaluronic fillers, with rest accounting for non hyaluronic acid fillers.
  • The dermal fillers market report presents an in-depth analysis of the various companies that are engaged in the global dermal fillers industry, across different segments, as defined below:

Why luck plays such a big role in hockey

Retrieved on: 
torsdag, april 18, 2024
Finger, Bruise, NHL, Baseball, Ice, NBA, Hockey, Probability, Travel, Football, Sport, Sports equipment

In the NHL, it is estimated that the contribution of luck to a team’s season record is approximately 53%.

Key Points: 
  • In the NHL, it is estimated that the contribution of luck to a team’s season record is approximately 53%.
  • The more chances a team has, the less luck plays a role in the outcome.
  • Luck plays much more of a role when the opportunities to score are lower.
  • Deflect, deflect, deflect
    The outsize role of luck in hockey can also be explained by an additional factor.

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

Retrieved on: 
tisdag, april 9, 2024
Eurostat, Diagnosis, Civil service commission, Brain, B cell, Gaucher's disease, Cell, CD34, Bone marrow, Bleeding, Disease, Seizure, Bruise, Patient, Committee, Knowledge, Fracture, Spleen, Regulation, Fatigue, Autotransplantation, EMA, IRIS, Human, Life expectancy, Eye, Bone pain, Anemia, European, COMP, Sponsor, European Commission, Safety, PPD, Marketing, Liver, Medicine, Pharmaceutical industry

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

Key Points: 


Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

Retrieved on: 
onsdag, mars 20, 2024
OTC Markets Group, Neurogenic bladder dysfunction, Death, Ampakine, DOI, Tetraplegia, Rat, Incidence, Bourbeau, Risk, Bruise, Patient, Research, University, Bladder cancer, Quality of life, Pleasure, EMG, Alom, Catheter, AMPA, Injury, Interim, CSO, Bangladesh Technical Education Board, Urinary tract infection, Respiration, Animal, Kidney, SCI, Rana, RespireRx

Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).

Key Points: 
  • Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).
  • Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications.
  • The present paper, entitled “Acute ampakines increase voiding function and coordination in a rat model of SCI” (Rana, Alom et al.
  • We believe that this research has the potential to represent a novel, breakthrough in the treatment of SCI, which is badly needed.”

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
onsdag, mars 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
onsdag, mars 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Distinctive Dermatology Introduces Cutting-Edge Technology to Reverse Aging Without Pain or Downtime

Retrieved on: 
onsdag, april 3, 2024
Skin care, Elastin, Face, Hyaluronic acid, Lifting, Bruise, Patient, Artificial intelligence, Skin, Collagen, Needle, Ageing, Medical imaging

Data shows for most effective results in reducing wrinkles, lifting muscles, and improving facial tone, patients need four treatments of EMface -- one per week.  Optimal results are noticeable 6 to 12 weeks after four treatments.

Key Points: 
  • ST. LOUIS, April 3, 2024 /PRNewswire/ -- Distinctive Dermatology , a leading St. Louis-area dermatology practice, is the first to offer groundbreaking technology that reverses aging and reduces wrinkles without discomfort, needles, or downtime.
  • The clinic is hosting "Hello Spring," a complimentary beauty/makeover event on April 11 for those who want to try it.
  • "EMface is the wave of the future for those wanting to reverse aging," says Angela Sutton, D.O.
  • Distinctive Dermatology provides medical and surgical care to patients with skin conditions, and cosmetic procedures to those wanting lifelong healthy skin.